105102-21-4 Usage
Uses
Used in Pharmaceutical Industry:
Torbafylline is used as an anti-inflammatory agent for its ability to inhibit the production of inflammatory cytokines, reducing inflammation in various disease states.
Torbafylline is used as an anti-fibrotic agent for its ability to inhibit the activation and proliferation of fibroblasts, preventing the excessive formation of scar tissue in fibrotic diseases.
Used in Respiratory Medicine:
Torbafylline is used as a therapeutic agent for the treatment of chronic obstructive pulmonary disease (COPD) due to its potential therapeutic effects in managing inflammation and fibrosis associated with the condition.
Used in Treatment of Inflammatory Conditions:
Torbafylline is used as a potential therapeutic agent for the treatment of other inflammatory conditions, leveraging its anti-inflammatory and anti-fibrotic properties to alleviate symptoms and improve patient outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 105102-21-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,5,1,0 and 2 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 105102-21:
(8*1)+(7*0)+(6*5)+(5*1)+(4*0)+(3*2)+(2*2)+(1*1)=54
54 % 10 = 4
So 105102-21-4 is a valid CAS Registry Number.
InChI:InChI=1/C16H26N4O4/c1-5-24-11-19-10-17-13-12(19)14(21)20(15(22)18(13)4)9-7-6-8-16(2,3)23/h10,23H,5-9,11H2,1-4H3
105102-21-4Relevant academic research and scientific papers
Pharmaceutical combination preparations containing cephalosporin and xanthine derivatives and their use
-
, (2008/06/13)
Pharmaceutical combination preparations containing cefotaxime and at least one xanthine derivative are suitable for the treatment of bacterial infectious diseases and for the treatment of septic shock.
Tertiary hydroxyalkylxanthines, medicaments containing them and their use
-
, (2008/06/13)
Tertiary hydroxyalkylxanthines having the general formula (I), characterized by the fact that at least one of the residues R1 and R3 represents a tertiary hydroxyalkyl group of formula (Ia) in which R4 represents an alkyl group having up to 3 carbon atoms and n a whole number from 2 to 5; the other residue which may remain R1 or R3 is a hydrogen atom or an aliphatic hydrocarbon residue R5 having up to 6 carbon atoms, in which the carbon chain may be separated by a maximum of two oxygen atoms or be substituted by an oxo group or two hydroxy groups at the most, and R2 represents an alkyl group with 1 to 4 carbon atoms. Also described is a process for manufacturing these compounds, which are suitable for the manufacture of medicines, in particular for use in the prevention and/or treatment of peripheral and/or cerebral irrigation disorders. STR1
